MedTrace Logo

SB17170 Phase 1 Clinical Trial in Solid Tumors

NCT05522868 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-11-20

No results posted yet for this study

Summary

Phase 1 Open-label, multicenter, dose escalation, dose expansion study

Conditions

Interventions

DRUG

SB17170

SB17170 capsules, Oral administration 21days/cycle

Sponsors & Collaborators

  • SPARK Biopharma

    lead INDUSTRY

Principal Investigators

  • Soojin Jun · SPARK Biopharma

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-17
Primary Completion
2027-06-30
Completion
2027-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05522868 on ClinicalTrials.gov